[PubMed: 3369412] 685
Mounjaro is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management in adults with obesity or overweight with comorbidities
By fasting for significant periods, we can reduce the prevalence of inflammatory markers, while increasing certain growth hormones that promote muscle growth, bone health, and metabolism
(2000) Heffernan, Jiang, Thorburn, and Ng evaluated the metabolic effects of orally administered AOD-9604 in rodent models and the lipolytic activity of the compound on isolated human adipose tissue ex vivo
GHK-Cu (copper peptide) is a lab-tested copper(II)-binding tripeptide (3 amino acids, copper complex)
Activation of GIP receptors and GLP-1 remains a focus of research due to their involvement in glucose-dependent insulin secretion, modulation of glucagon secretion, regulation of gastric emptying and mechanisms related to the control of satiety and energy intake
